Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATYR NYSE:MBX NASDAQ:SCLX NASDAQ:SLDB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATYRaTyr Pharma$5.35+8.1%$5.30$1.67▼$7.29$524.23M0.944.96 million shs6.03 million shsMBXMBX Biosciences$14.33+1.3%$12.51$4.81▼$27.50$481.40MN/A328,877 shs280,074 shsSCLXScilex$18.87+10.1%$10.61$3.60▼$45.15$119.22M1.32313,464 shs465,891 shsSLDBSolid Biosciences$5.93+4.8%$5.74$2.41▼$10.07$440.74M2.441.16 million shs794,407 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATYRaTyr Pharma+8.08%+9.18%-19.06%+42.67%+184.57%MBXMBX Biosciences+1.27%-2.65%+4.75%+17.94%+1,432,999,900.00%SCLXScilex+10.09%+4.37%+66.11%+314.73%-56.52%SLDBSolid Biosciences+4.77%-2.95%-12.28%+111.03%-40.40%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATYRaTyr Pharma2.5237 of 5 stars3.61.00.00.03.31.70.6MBXMBX Biosciences1.9636 of 5 stars3.50.00.00.01.11.70.6SCLXScilex2.4471 of 5 stars3.32.00.00.03.11.70.6SLDBSolid Biosciences3.266 of 5 stars4.62.00.00.02.11.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATYRaTyr Pharma 3.17Buy$23.25334.58% UpsideMBXMBX Biosciences 3.00Buy$37.63162.56% UpsideSCLXScilex 2.50Moderate Buy$455.002,311.23% UpsideSLDBSolid Biosciences 3.17Buy$15.00152.95% UpsideCurrent Analyst Ratings BreakdownLatest SCLX, MBX, ATYR, and SLDB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/22/2025ATYRaTyr PharmaJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$9.00 ➝ $17.008/14/2025SLDBSolid BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.008/14/2025SLDBSolid BiosciencesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$15.00 ➝ $13.008/13/2025SLDBSolid BiosciencesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$17.00 ➝ $14.008/5/2025MBXMBX BiosciencesMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$38.007/21/2025SLDBSolid BiosciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOverweight ➝ Overweight$16.007/16/2025MBXMBX BiosciencesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$38.006/26/2025SLDBSolid BiosciencesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$14.006/26/2025SLDBSolid BiosciencesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$14.006/20/2025ATYRaTyr PharmaWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$17.00 ➝ $25.006/17/2025SLDBSolid BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATYRaTyr PharmaN/AN/AN/AN/A$0.76 per shareN/AMBXMBX BiosciencesN/AN/AN/AN/AN/AN/ASCLXScilex$56.59M2.32N/AN/A($35.80) per share-0.53SLDBSolid Biosciences$8.09M57.08N/AN/A$3.32 per share1.79Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATYRaTyr Pharma-$64.02M-$0.80N/AN/AN/AN/A-93.69%-68.83%11/6/2025 (Estimated)MBXMBX BiosciencesN/A-$4.54N/AN/AN/AN/AN/AN/AN/ASCLXScilex-$72.81M-$29.02N/AN/AN/A-179.12%N/A-109.95%N/ASLDBSolid Biosciences-$124.70M-$2.80N/AN/AN/AN/A-69.70%-56.74%11/5/2025 (Estimated)Latest SCLX, MBX, ATYR, and SLDB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025SCLXScilex-$4.55-$7.42-$2.87-$7.42$26.25 million$9.90 million8/12/2025Q2 2025SLDBSolid Biosciences-$0.51-$0.42+$0.09-$0.42N/AN/A8/7/2025Q2 2025ATYRaTyr Pharma-$0.18-$0.22-$0.04-$0.22N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATYRaTyr PharmaN/AN/AN/AN/AN/AMBXMBX BiosciencesN/AN/AN/AN/AN/ASCLXScilexN/AN/AN/AN/AN/ASLDBSolid BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATYRaTyr Pharma0.015.635.63MBXMBX BiosciencesN/AN/AN/ASCLXScilexN/A0.110.10SLDBSolid BiosciencesN/A9.349.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATYRaTyr Pharma61.72%MBXMBX BiosciencesN/ASCLXScilex69.67%SLDBSolid Biosciences81.46%Insider OwnershipCompanyInsider OwnershipATYRaTyr Pharma3.70%MBXMBX Biosciences52.19%SCLXScilex7.94%SLDBSolid Biosciences1.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATYRaTyr Pharma5397.99 million94.36 millionOptionableMBXMBX Biosciences3633.59 millionN/AN/ASCLXScilex806.96 million6.40 millionOptionableSLDBSolid Biosciences10077.87 million76.39 millionOptionableSCLX, MBX, ATYR, and SLDB HeadlinesRecent News About These CompaniesMonashee Investment Management LLC Grows Position in Solid Biosciences Inc. $SLDBAugust 23 at 8:31 AM | marketbeat.comLeerink Partnrs Issues Optimistic Forecast for SLDB EarningsAugust 19, 2025 | marketbeat.comQ3 EPS Forecast for Solid Biosciences Increased by AnalystAugust 19, 2025 | americanbankingnews.comQ1 Earnings Forecast for SLDB Issued By Leerink PartnrsAugust 17, 2025 | marketbeat.comFY2025 EPS Estimate for Solid Biosciences Boosted by AnalystAugust 17, 2025 | marketbeat.comHC Wainwright Forecasts Lower Earnings for Solid BiosciencesAugust 17, 2025 | marketbeat.comQ3 Earnings Estimate for Solid Biosciences Issued By WedbushAugust 17, 2025 | marketbeat.comJPMorgan Chase & Co. Cuts Solid Biosciences (NASDAQ:SLDB) Price Target to $13.00August 17, 2025 | americanbankingnews.comLeerink Partnrs Weighs in on SLDB Q1 EarningsAugust 17, 2025 | americanbankingnews.comSolid Biosciences (NASDAQ:SLDB) Upgraded at Wall Street ZenAugust 17, 2025 | marketbeat.comSolid Biosciences' (SLDB) "Buy" Rating Reiterated at Chardan CapitalAugust 17, 2025 | americanbankingnews.comHC Wainwright Brokers Reduce Earnings Estimates for SLDBAugust 17, 2025 | americanbankingnews.comSolid Biosciences (NASDAQ:SLDB) Given "Buy" Rating at Chardan CapitalAugust 16, 2025 | marketbeat.comSolid Biosciences (NASDAQ:SLDB) Price Target Lowered to $13.00 at JPMorgan Chase & Co.August 16, 2025 | marketbeat.comHC Wainwright Predicts Lower Earnings for Solid BiosciencesAugust 16, 2025 | marketbeat.comSolid Biosciences (NASDAQ:SLDB) Shares Up 9.9% Following Better-Than-Expected EarningsAugust 15, 2025 | marketbeat.comWedbush Lowers Solid Biosciences (NASDAQ:SLDB) Price Target to $14.00August 15, 2025 | marketbeat.com40,930 Shares in Solid Biosciences Inc. (NASDAQ:SLDB) Purchased by XTX Topco LtdAugust 15, 2025 | marketbeat.comSolid Biosciences (NASDAQ:SLDB) Trading 9.9% Higher on Strong EarningsAugust 15, 2025 | americanbankingnews.comSolid Biosciences (NASDAQ:SLDB) Posts Earnings Results, Beats Estimates By $0.09 EPSAugust 14, 2025 | marketbeat.comSolid Biosciences Inc.: Solid Biosciences Reports Second Quarter 2025 Financial Results and Provides Business UpdatesAugust 13, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSCLX, MBX, ATYR, and SLDB Company DescriptionsaTyr Pharma NASDAQ:ATYR$5.35 +0.40 (+8.08%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$5.38 +0.03 (+0.47%) As of 08/22/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.MBX Biosciences NYSE:MBX$14.33 +0.18 (+1.27%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$14.34 +0.01 (+0.03%) As of 08/22/2025 06:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.Scilex NASDAQ:SCLX$18.87 +1.73 (+10.09%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$18.93 +0.06 (+0.34%) As of 08/22/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California.Solid Biosciences NASDAQ:SLDB$5.93 +0.27 (+4.77%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$5.90 -0.03 (-0.57%) As of 08/22/2025 05:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Workday: Institutions Are Buying This Stock, Shouldn’t You? Alphabet’s Breakout Potential: From Laggard to AI Leader After Earnings Miss, Walmart Is Still a Top Consumer Staples Play Should You Join Buffett and Invest in Constellation Brands? Can Identity Security Fuel CrowdStrike’s Next Growth Phase? 3 Robotics Stocks at the Heart of the Robotics Revolution Analog Devices and an AI-Driven Semiconductor Supercycle Shopify’s Risk-Reward Profile Is Suddenly Red Hot Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.